All studies
RecruitingPHASE1, PHASE2INTERVENTIONAL

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

This early-stage clinical trial is looking at a new cancer medicine called AZD0305 for people with multiple myeloma. Multiple myeloma is a cancer of the plasma cells, which are white blood cells found in your bone marrow. The main goal of the trial is to find out the safest dose of AZD0305 and see how well it works. Researchers are testing AZD0305 on its own and in combination with other existing myeloma medicines, such as elranatamab or pomalidomide with dexamethasone. The study is designed for adults whose myeloma has come back or stopped responding after several past treatments. Taking part involves regular clinic visits, regular health checks, and careful monitoring by a specialist medical team.

At a glance

Status
Recruiting
Phase
PHASE1, PHASE2
Sponsor
AstraZeneca
Enrolment target
226
Start
05 Dec 2023
Estimated completion
24 Jan 2028

What is this study about?

Multiple myeloma is a type of blood cancer that develops from plasma cells inside the bone marrow. Plasma cells normally help protect the body by making antibodies to fight off infections. In multiple myeloma, abnormal plasma cells multiply too quickly and crowd out healthy blood cells, which can cause bone damage, kidney problems, and severe tiredness. While treatments for multiple myeloma have improved greatly, the cancer often returns or stops responding to medications over time. Because of this, doctors are continually searching for new and more effective options.

This trial is looking at an experimental medicine called AZD0305. It is being tested to find out if it can help slow down or stop the growth of cancer cells when previous treatments have stopped working. Researchers want to understand how the body handles the drug, what side effects it might cause, and what the safest and most effective dose is.

The study is divided into different groups, known as modules. In one group, participants receive AZD0305 alone. In other groups, participants receive AZD0305 together with other approved myeloma drugs, such as elranatamab or a combination of pomalidomide and dexamethasone. Combining medicines can sometimes help them work better together to fight cancer cells.

By taking part, participants help doctors learn whether AZD0305 could become a useful new treatment option for people living with advanced multiple myeloma in the future.

Key takeaways

  • Tests a new medicine, AZD0305, for people with advanced multiple myeloma.
  • Aims to find safe doses and see how well the drug works alone or combined with other therapies.
  • Aimed at adults whose cancer has returned after several previous treatments.
  • All participants receive the study drug; no placebo is used.
  • Participation involves regular hospital visits, health monitoring, and blood tests.

Who may be eligible?

This trial is open to adults aged 18 and over who have confirmed multiple myeloma that can be measured through standard blood or urine tests. To be suitable, participants must have already tried other myeloma treatments that have either stopped working or are no longer suitable for them. In most cases, you will need to have had at least three prior courses of cancer therapy.

You will also need to be reasonably active and able to look after yourself, with your liver, kidneys, and bone marrow functioning well enough to take part safely. The trial team will run detailed checks during an initial screening visit to ensure that taking part is as safe as possible for you.

You will not be able to join this study if you have certain other related blood disorders, such as smoldering multiple myeloma or amyloidosis. People who have had certain specific cancer medicines in the past, have had another cancer in the last three years, or have a severe allergy to the trial drugs will also not be eligible.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or over.
  2. I have been diagnosed with multiple myeloma.
  3. My cancer has come back or stopped responding to past treatments (usually after at least 3 prior treatments).
  4. I am well enough to carry out daily activities and look after myself.
  5. I do not have other conditions like smoldering myeloma or amyloidosis.
Answer every question to see your result.

What does participation involve?

If you decide to take part, your care will be overseen by a specialist hospital cancer team. First, you will attend screening visits to have blood tests, urine tests, heart checks, and possibly bone marrow samples or scans to check your eligibility. If you join, you will be placed into a treatment group receiving AZD0305 either on its own or with other medicines. The study medicine is given at regular hospital appointments, either as an injection or through a drip into a vein. You will need to attend frequent clinic visits so the team can monitor your health and check how your body responds. Treatment continues as long as the medicine is helping you and side effects remain manageable, followed by regular check-ins to monitor your long-term health.

Potential risks and benefits

The main benefit of taking part is the possibility that the trial medicine may help control your myeloma when other treatments have failed, while also helping doctors improve future cancer care. However, because AZD0305 is experimental, there is no guarantee it will work for you. New medicines can also cause unexpected or uncomfortable side effects, which the medical team will explain in detail and monitor closely. Joining is completely voluntary, and you are free to leave the trial at any time without your regular NHS care being affected.

Locations (46)

  • Research Site
    Verified postcode
    Duarte, United States· Recruiting
  • Research Site
    Verified postcode
    Irvine, United States· Recruiting
  • Research Site
    Verified postcode
    Atlanta, United States· Recruiting
  • Research Site
    Verified postcode
    Boston, United States· Recruiting
  • Research Site
    Verified postcode
    Ann Arbor, United States· Recruiting
  • Research Site
    Verified postcode
    St Louis, United States· Withdrawn
  • Research Site
    Verified postcode
    New York, United States· Recruiting
  • Research Site
    Verified postcode
    Philadelphia, United States· Recruiting
  • Research Site
    Verified postcode
    Fairfax, United States· Recruiting
  • Research Site
    Verified postcode
    Fitzroy, Australia· Recruiting
  • Research Site
    Verified postcode
    Melbourne, Australia· Recruiting
  • Research Site
    Verified postcode
    Nedlands, Australia· Recruiting

Common questions

Will I receive the new study medicine?

Yes. This is an 'open-label' trial without a dummy drug (placebo), meaning all participants will receive AZD0305, either on its own or alongside other cancer medications.

Do I have to pay to take part in this trial?

No. The study medications and trial-related tests are provided free of charge, and you will not have to pay for your trial care.

Can I leave the study if I change my mind?

Yes. You have the right to withdraw from the study at any time for any reason, and your regular doctor will support you with other available treatments.

Will taking part cure my myeloma?

Multiple myeloma is generally not considered curable with current treatments. The aim of this trial is to control the cancer, help manage symptoms, and test the medicine's safety.

How often will I need to visit the hospital?

You will need to visit the hospital quite frequently, particularly in the first few months, for treatment, blood tests, and health checks. Your trial team will give you a clear schedule.

How to find out more

AstraZeneca Clinical Study Information Center

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "AZD0305 as Monotherapy or in Combination With Anticancer Age…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.